Author:
Rawat Alisha, ,Sajwan Meenakshi,Chandola Yamini,Nautiyal Himani,Nainwal Nidhi
Abstract
Hepatocellular carcinoma (HCC) is constantly seeking the interest of researchers as an untreatable and fatal disease, attaining second position so far worldwide. Our study provides us an opportunity to explore new potential therapeutic combinations in this regard. We hypothesized that the anticancer activity of imipramine, which is used as an antidepressant drug, can be potentiated with an adjuvant, niacin, thereby providing a better treatment approach. The combination turned out to show beneficial alterations in various liver function test, caspase 3 (antiapoptotic) activity, tumor growth and survival profile of animals, precisely in our therapeutic group involving imipramine and niacin combination post diethyl nitrosamine (DENA) dose and hepatocellular carcinoma induction. Results demonstrated a remarkable restoration in all liver enzymes in the therapeutic groups.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference33 articles.
1. Liu Z., Jiang Y., Yuan H., Fang Q., Cai N., Suo C., Jin L., Zhang T. and Chen X.: The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention, J Hepatol., 2019, 70(4) 674-683.
2. 2. Wolter K. and Zender L.: Therapy-induced senescence - an induced synthetic lethality in liver cancer? Nat Rev. Gastroenterol Hepatol., 2020, 17(3):135-136.
3. 3. Sharma R.: Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries, Jpn J Clin Oncol., 2020, 50(12) 1370-1379.
4. 4. Pimpin L., Cortez-Pinto H., Negro F., Corbould E., Lazarus J.V., Webber L. and Sheron N.: EASL HEPA Health Steering Committee. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies, J Hepatol., 2018, 69 (3) 718-735.
5. 5. Zheng R., Qu C., Zhang S., Zeng H., Sun K., Gu X., Xia C., Yang Z., Li H., Wei W., Chen W. and He J.: Liver cancer incidence and mortality in China, Chin J Cancer Res, 2018, 30(6) 571-579.